We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Mawi DNA

Mawi DNA Technologies develops unique biosample collection technologies enabling universal sample collection from any... read more Featured Products: More products

Download Mobile App




Whole Blood Collection Technology Enables Isolation of cfDNA, CTC, and RNA from Same Sample

By LabMedica International staff writers
Posted on 03 Aug 2022

RNA is a crucial tool in advancing our understanding of health and disease in humans and animals. More...

However, RNA is particularly fragile and degrades quickly as soon the cells leave the internal environment of the body, such as when blood is drawn. A reliable technology to stabilize the sample right after collection is needed to reduce the degradation rate and maintain RNA integrity for proper analysis. Currently, efficient stabilization of RNA in body fluids, cells or tissues requires expensive cold chain involvement or relatively toxic fixative, which increases the cost per sample and urgency for processing the sample, leaving very little room for error. Whole blood can be a great source of stable RNA. However, commercially available whole blood collection tubes for RNA stabilization have certain limitations. Now, a groundbreaking product for ambient collection, stabilization, and transportation of whole blood samples enables isolation of cfDNA, CTC, and RNA from the same sample. Collected cells are maintained intact, making them also suitable for FACS analysis.

In order to overcome existing hurdles and enable widespread and efficient collection and analysis of whole blood, Mawi DNA Technologies (Hayward, CA, USA) has developed the HemaSure-OMICs Collection Tube products that offer non-toxic stabilization of whole blood, free of formaldehyde or formaldehyde-like ingredients. HemaSure-OMICs Whole Blood Collection Tubes are validated for room temperature stabilization of viral DNA and RNA for several days in viral load and detection assays applicable to the HIV, MERS-CoV, 2019-nCoV and other DNA and RNA viruses.

cfDNA (up to 14 days), CTC (up to 8 days), and RNA (up to 8 days) are stabilized at room temperature in the same blood tube (temperature range of 25° – 45° C). HemaSure-OMICs Whole Blood Collection Tubes are available in 3, 6, and 9 mL plastic vacuum filled blood collection tubes as well as a 250µl microtainer for blood drops for easy shipping and durability. They are compatible with any commercially available manual or automation-enabled kits for the purification of cfDNA and CTC from whole blood. HemaSure-OMICs Whole Blood Collection Tubes are for research use only and not for use in diagnostic or therapeutic procedures.

Related Links:
Mawi DNA Technologies


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.